InvestorsHub Logo
Followers 56
Posts 1134
Boards Moderated 1
Alias Born 01/13/2017

Re: None

Tuesday, 01/31/2017 10:05:12 PM

Tuesday, January 31, 2017 10:05:12 PM

Post# of 203914
Interesting read on another OTC stock that is advancing MMJ with the FDA: AXIM.

http://analysis.secfilings.com/articles/148-axim-biotech-building-a-lower-cost-portfolio-of-cannabinoid-therapeutics

OWCP will use the same playbook for all FDA approved cremes, and then for illnesses treated with the sublingual tablet.

As I've said before, I'm positive top MBA programs this year will do a case study comparison of the traditional GWPH route vs the new OWCP/AXIM route.